Ratings Mitsui Chemicals, Inc.

Equities

4183

JP3888300005

Market Closed - Japan Exchange 02:00:00 2024-03-28 am EDT 5-day change 1st Jan Change
4,426 JPY -0.81% Intraday chart for Mitsui Chemicals, Inc. -2.47% +5.83%

Strengths

  • With regards to fundamentals, the enterprise value to sales ratio is at 0.81 for the current period. Therefore, the company is undervalued.
  • The company appears to be poorly valued given its net asset value.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company is in debt and has limited leeway for investment
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Commodity Chemicals

1st Jan change Capi. Investor Rating ESG Refinitiv
+5.83% 5.69B
B+
+9.65% 109B
A-
-7.78% 61.6B
A-
+3.80% 34.64B
B
+9.05% 31.17B
B
+8.28% 33.41B
A-
+8.85% 19.53B
B-
+9.18% 18.93B
B+
+5.01% 15.7B
C+
+3.86% 14.64B
B
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes